Viewing Then Doing?: Problem-Solving Court Coordinators’ Perceptions of Medications for Opioid Use Disorders from a Nationally Representative Survey in the United States

References

• Amato, L., Davoli, M. A., Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28(4), 321–329. https://doi.org/10.1016/j.jsat.2005.02.007
   PubMed Web of Science ®Google Scholar
• Andraka-Christou, B. T. (2016). Social and legal perspectives on underuse of medication-assisted treatment for opioid dependence [Doctoral dissertation]. Indiana University. Theses and Dissertations of Digital Repository at Maurer Law.
   Google Scholar
• Andraka-Christou, B., & Atkins, D. (2020a). Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff. American Journal of Drug and Alcohol Abuse, 46(6), 749–760. https://doi.org/10.1080/00952990.2020.1807559
   PubMed Web of Science ®Google Scholar
• Andraka-Christou, B., & Atkins, D. N. (2020b). Whose opinion matters about medications for opioid use disorder? A cross-sectional survey of social norms among court staff. Substance Abuse, 42(4), 735–750. https://doi.org/10.1080/08897077.2020.1846666
   PubMed Web of Science ®Google Scholar
• Berman, G., & Feinblatt, J. (2001). Problem‐solving courts: A brief primer. Law & Policy, 23(2), 125–140. https://doi.org/10.1111/1467-9930.00107
   Google Scholar
• Center for Behavioral Health Statistics and Quality. (2015). 2014 national survey on drug use and health: Methodological summary and definitions. Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Clark, R. E., Samnaliev, M., Baxter, J. D., & Leung, G. Y. (2011). The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs (Project Hope), 30(8), 1425–1433. https://doi.org/10.1377/hlthaff.2010.0532
   PubMed Web of Science ®Google Scholar
• Comer, S., Cunningham, C., Fishman, M. J., Gordon, A., Kampman, K., Langleben, D., Nordstrom, B., Oslin, D., Woody, G., Wright, T., Wyatt, S., Femino, J., Jarvis, M., Kotz, M., Pirard, S., Roose, R. J., Geier-Horan, A., Haynes, B., Mills, P. S., & Miller, M. M. (2015). National practice guideline for the use of medications in the treatment of addiction involving opioid use. https://newmexico.networkofcare.org/content/client/1446/2.6_17_AsamNationalPracticeGuidelines.pdf
   Google Scholar
• D’Aunno, T., Pollack, H. A., Frimpong, J. A., & Wuchiett, D. (2014). Evidence-based treatment for opioid disorders: A 23-year national study of methadone dose levels. Journal of Substance Abuse Treatment, 47(4), 245–250. https://doi.org/10.1016/j.jsat.2014.06.001
   PubMed Web of Science ®Google Scholar
• Evans, E. A., Wilson, D., & Friedmann, P. D. (2022). Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 231, 109254. https://doi.org/10.1016/j.drugalcdep.2021.109254
   PubMed Web of Science ®Google Scholar
• Faragó, F., Blue, T. R., Smith, L. R., Witte, J. C., Gordon, M., & Taxman, F. S. (2023). Medication-assisted treatment in problem-solving courts: A national survey of state and local court coordinators. Journal of Drug Issues, 53(2), 296–320. https://doi.org/10.1177/00220426221109948
   Web of Science ®Google Scholar
• Fendrich, M., & LeBel, T. P. (2019). Implementing access to medication assisted treatment in a drug treatment court: Correlates, consequences, and obstacles. Journal of Offender Rehabilitation, 58(3), 178–198. https://doi.org/10.1080/10509674.2019.1582573
   Web of Science ®Google Scholar
• Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., Barry, D. T., O’Connor, P. G., & Schottenfeld, R. S. (2008). Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. American Journal on Addictions, 17(2), 116–120. https://doi.org/10.1080/10550490701860971
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2019). Information about medication-assisted treatment (MAT). FDA. https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat
   Google Scholar
• Friedmann, P. D., Rhodes, A. G., & Taxman, F, Step’n Out Research Group of CJ-DATS. (2009). Collaborative behavioral management: Integration and intensification of parole and outpatient addiction treatment services in the Step’n Out study. Journal of Experimental Criminology, 5(3), 227–243. https://doi.org/10.1007/s11292-009-9079-3
   PubMed Web of Science ®Google Scholar
• Friedmann, P. D., Hoskinson, R., Gordon, M., Schwartz, R., Kinlock, T., Knight, K., Flynn, P. M., Welsh, W. N., Stein, L. A. R., Sacks, S., O’Connell, D. J., Knudsen, H. K., Shafer, M. S., Hall, E., & Frisman, L. K, Mat Working Group of CJ-Dats. (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers, and intentions. Substance Abuse, 33(1), 9–18. https://doi.org/10.1080/08897077.2011.611460
   PubMed Web of Science ®Google Scholar
• Gallagher, J. R., Wahler, E. A., Minasian, R. M., & Edwards, A. (2019). Treating opioid use disorders in drug court: Participants’ views on using medication-assisted treatments (MATs) to support recovery. International Criminal Justice Review, 29(3), 249–261. https://doi.org/10.1177/1057567719846227
   Web of Science ®Google Scholar
• Garcia, C. A., Correa, G. C., Viver, A. D. H., Kinlock, T. W., Gordon, M. S., Avila, C. A., Reyes, I. C., & Schwartz, R. P. (2007). Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. Journal of Addiction Medicine, 1(3), 126–132. https://doi.org/10.1097/ADM.0b013e31814b8880
   PubMed Web of Science ®Google Scholar
• Gold, M. S. (1993). Opiate addiction and the locus coeruleus: The clinical utility of clonidine, naltrexone, nethadone, and buprenorphine. Psychiatric Clinics of North America, 16(1), 61–73. https://doi.org/10.1016/S0193-953X(18)30190-4
   PubMed Web of Science ®Google Scholar
• Henderson, C. E., Young, D. W., Farrell, J., & Taxman, F. S. (2009). Associations among state and local organizational contexts: Use of evidence-based practices in the criminal justice system. Drug and Alcohol Dependence, 103 (Suppl 1), S23–S32. PMID: 19174321
   PubMedGoogle Scholar
• Johnson, B. A. (2008). Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochemical Pharmacology, 75(1), 34–56. https://doi.org/10.1016/j.bcp.2007.08.005
   PubMed Web of Science ®Google Scholar
• Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine, New York, 67(5–6), 347–364.
   PubMed Web of Science ®Google Scholar
• Kaiser, K. A., & Holtfreter, K. (2016). An integrated theory of specialized court programs: Using procedural justice and therapeutic jurisprudence to promote offender compliance and rehabilitation. Criminal Justice and Behavior, 43(1), 45–62. https://doi.org/10.1177/0093854815609642
   Web of Science ®Google Scholar
• Knight, D. K., Belenko, S., Wiley, T., Robertson, A. A., Arrigona, N., Dennis, M., Bartkowski, J. P., McReynolds, L. S., Becan, J. E., Knudsen, H. K., Wasserman, G. A., Rose, E., DiClemente, R., & Leukefeld, C., JJ-TRIALS Cooperative. (2015). Juvenile justice—Translational research on interventions for adolescents in the legal system (JJ-TRIALS): A cluster randomized trial targeting system-wide improvement in substance use services. Implementation Science, 11(1), 1–18. https://doi.org/10.1186/s13012-016-0423-5
   Google Scholar
• Krawczyk, N., Picher, C. E., Feder, K. A., & Saloner, B. (2017). Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Affairs (Project Hope), 36(12), 2046–2053. https://doi.org/10.1377/hlthaff.2017.0890
   PubMed Web of Science ®Google Scholar
• Kresina, T., Litwin, A., Marion, I., Lubran, R., & Clark, H. (2009). United States government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. Journal of Drug Policy Analysis, 2(1), 1–23. https://doi.org/10.2202/1941-2851.1007
   Google Scholar
• Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/10.7326/M17-3107
   PubMed Web of Science ®Google Scholar
• Marlowe, D., Hardin, C., & Fox, C. (2016). Painting the current picture: A national report on drug courts and other problem-solving courts in the United States (pp. 88). National Drug Court Institute.
   Google Scholar
• Matusow, H., Dickman, S. L., Rich, J. D., Fong, C., Dumont, D. M., Hardin, C., Marlowe, D., & Rosenblum, A. (2013). Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of Substance Abuse Treatment, 44(5), 473–480. https://doi.org/10.1016/j.jsat.2012.10.004
   PubMed Web of Science ®Google Scholar
• Mollman, M., & Mehta, C. (2017). Neither justice nor treatment: Drug courts in the United States. Physicians for Human Rights. https://pbpd.org.br/wp-content/uploads/2017/06/PHR_DrugCourts_Report.pdf
   Google Scholar
• Moore, K. E., Siebert, S. L., Kromash, R., Owens, M. D., & Allen, D. C. (2022). Negative attitudes about medications for opioid use disorder among criminal legal staff. Drug and Alcohol Dependence Reports, 3, 100056. https://doi.org/10.1016/j.dadr.2022.100056
   PubMedGoogle Scholar
• Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018). Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 85(1), 90–96. https://doi.org/10.1016/j.jsat.2017.07.001
   PubMedGoogle Scholar
• National Association of Drug Court Professionals (NADCP). (2013). Adult Drug Court Best Practice Standards (Vol. I). Alexandria, VA. https://www.nadcp.org/wp-content/uploads/2018/12/Adult-Drug-Court-Best-Practice-Standards-Volume-I-Text-Revision-December-2018-1.pdf
   Google Scholar
• National Association of Drug Court Professionals (NADCP). (2015). Adult Drug Court Best Practice Standards (Vol. 2). Alexandria, VA. https://www.nadcp.org/wp-content/uploads/2018/12/Adult-Drug-Court-Best-Practice-Standards-Volume-2-Text-Revision-December-2018-1.pdf
   Google Scholar
• National Drug Court Resource Center. (2021). Treatment court counts. Data Digest, 1(2), 1–16. https://ndcrc.org/data-digest/
   Google Scholar
• Nunn, A., Zaller, N., Dickman, S., Trimbur, C., Nijhawan, A., & Rich, J. D. (2009). Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence, 105(1–2), 83–88. https://doi.org/10.1016/j.drugalcdep.2009.06.015
   PubMed Web of Science ®Google Scholar
• Oesterle, T. S., Thusius, N. J., Rummans, T. A., & Gold, M. S. (2019). Medication-assisted treatment for opioid-use disorder. Mayo Clinic Proceedings, 94(10), 2072–2086. https://doi.org/10.1016/j.mayocp.2019.03.029
   PubMed Web of Science ®Google Scholar
• Oser, C. B., Knudsen, H. K., Staton-Tindall, M., Taxman, F., & Leukefeld, C. (2009). Organizational-level correlates of the provision of detoxification services and medication-based treatments for substance abuse in correctional institutions. Drug and Alcohol Dependence, 103 (Suppl 1), S73–S81. https://doi.org/10.1016/j.drugalcdep.2008.11.005
   PubMedGoogle Scholar
• Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010). Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug and Alcohol Dependence, 106(1), 56–60. https://doi.org/10.1016/j.drugalcdep.2009.07.013
   PubMed Web of Science ®Google Scholar
• Rich, J. D., Boutwell, A. E., Shield, D. C., Key, R. G., McKenzie, M., Clarke, J. G., & Friedmann, P. D. (2005). Attitudes and practices regarding the use of methadone in US state and federal prisons. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 82(3), 411–419. https://doi.org/10.1093/jurban/jti072
   PubMed Web of Science ®Google Scholar
• Richard, E. L., Schalkoff, C. A., Piscalko, H. M., Brook, D. L., Sibley, A. L., Lancaster, K. E., Miller, W. C., & Go, V. F. (2020). You are not clean until you’re not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal on Drug Policy, 85, 102704. https://doi.org/10.1016/j.drugpo.2020.102704
   PubMed Web of Science ®Google Scholar
• Roman, P. M., & Johnson, J. A. (2004). National treatment center study: Summary report. Institute for Behavioral Research, University of Georgia.
   Google Scholar
• Taxman, F. S., Young, D. W., Wiersema, B., Rhodes, A., & Mitchell, S. (2007). The national criminal justice treatment practices survey: Multilevel survey methods and procedures. Journal of Substance Abuse Treatment, 32(3), 225–238. https://doi.org/10.1016/j.jsat.2007.01.002
   PubMed Web of Science ®Google Scholar
• Verma, J. P. (2015). Repeated measures design for empirical researchers. Wiley.
   Google Scholar